The Deal
Viatris Was Built on Generics. It Is Paying $1.65 Billion for Two Pain Drugs That Will Face Them.
Viatris has agreed to buy Pacira BioSciences for $36.50 a share in cash, about 45 per cent above Wednesday's close. It gets two non-opioid pain drugs with about $692 million of sales last year. Generic versions of the larger one, Exparel, are due to start arriving in early 2030 under patent settlements.
